Invention Publication
- Patent Title: NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN
-
Application No.: US18278498Application Date: 2022-02-21
-
Publication No.: US20240132893A1Publication Date: 2024-04-25
- Inventor: Masafumi MATSUO , Kazuhiro MAETA
- Applicant: KNC LABORATORIES CO., LTD.
- Applicant Address: JP Hyogo
- Assignee: KNC LABORATORIES CO., LTD.
- Current Assignee: KNC LABORATORIES CO., LTD.
- Current Assignee Address: JP Hyogo
- Priority: JP 21029890 2021.02.26
- International Application: PCT/JP2022/006907 2022.02.21
- Date entered country: 2023-08-22
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A23K20/153 ; A23L33/13 ; A61P21/00

Abstract:
A method of inhibiting the function of myostatin is provided.
An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target sequence in exon 3 of the myostatin gene and is capable of allowing the expression of a splicing variant of myostatin. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or suppressing muscle weakness, an agent for switching the splicing of the myostatin gene from production of myostatin to production of a splicing variant thereof, an agent for decreasing myostatin signaling, and an anticancer agent, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.
An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target sequence in exon 3 of the myostatin gene and is capable of allowing the expression of a splicing variant of myostatin. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or suppressing muscle weakness, an agent for switching the splicing of the myostatin gene from production of myostatin to production of a splicing variant thereof, an agent for decreasing myostatin signaling, and an anticancer agent, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.
Public/Granted literature
- US20240229036A9 NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN Public/Granted day:2024-07-11
Information query
IPC分类: